KoreaMed Synapse

Go to TopGo to Top Go to BottomGo to Bottom


1	Cost-effective BRCA Testing in Advanced Ovarian Cancer Myungshin Kim Ann Lab Med.2023;43(1):3-4. Published online 2022 September 1 DOI: http://dx.doi.org/10.3343/alm.2023.43.1.3

2	Effect of BRCA1/2 Mutational Status on Survival Outcomes According to Secondary Cytoreductive Surgery and Maintenance Therapy in Platinum-Sensitive Relapsed Ovarian Cancer: A Real-World Evidence Study Se Ik Kim, Hyunji Lim, Hee Seung Kim, Hyun Hoon Chung, Jae-Weon Kim, Noh Hyun Park, Yong-Sang Song, Maria Lee Cancer Res Treat.2023;55(1):245-257. Published online 2022 July 19 DOI: http://dx.doi.org/10.4143/crt.2022.232

3	Founder BRCA1 mutations in Nepalese population Anurag Mehta, Himanshi Diwan, Garima Gupta, Shrinidhi Nathany, Shalini Agnihotri, Surender Dhanda J Pathol Transl Med.2022;56(4):212-216. Published online 2022 June 15 DOI: http://dx.doi.org/10.4132/jptm.2022.05.02

4	Reclassification of Five BRCA1/2 Variants with Unknown Significance Using Complex Functional Study Anikó Bozsik, János Papp, Vince Kornél Grolmusz, Attila Patócs, Edit Oláh, Henriett Butz Cancer Res Treat.2022;54(4):970-984. Published online 2022 February 8 DOI: http://dx.doi.org/10.4143/crt.2021.1078

5	Clinicopathological Characterization of Double Heterozygosity for BRCA1 and BRCA2 Variants in Korean Breast Cancer Patients Yoon Ju Bang, Won Kyung Kwon, Seok Jin Nam, Seok Won Kim, Byung-Joo Chae, Se Kyung Lee, Jai Min Ryu, Jong-Won Kim, Jonghan Yu, Jeong Eon Lee Cancer Res Treat.2022;54(3):827-833. Published online 2021 October 13 DOI: http://dx.doi.org/10.4143/crt.2021.791

6	Disparities between Uptake of Germline BRCA1/2 Gene Tests and Implementation of Post-test Management Strategies in Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients Young Min Hur, Jaehee Mun, Mi-Kyung Kim, Maria Lee, Yun Hwan Kim, Seung-Cheol Kim J Korean Med Sci.2021;36(38):e241. Published online 2021 August 17 DOI: http://dx.doi.org/10.3346/jkms.2021.36.e241

7	Prevalence of tumor BRCA1 and BRCA2 dysfunction in unselected patients with ovarian cancer Roshni D. Kalachand, Ciaran O’Riain, Sinead Toomey, Aoife Carr, Kirsten M. Timms, Sharon O’Toole, Stephen Madden, Mark Bates, John J. O’Leary, Noreen Gleeson, Dearbhaile O’Donnell, Liam Grogan, Oscar Breathnach, Angela Farrelly, Britta Stordal, Bryan T. Hennessy Obstet Gynecol Sci.2020;63(5):643-654. Published online 2020 September 2 DOI: http://dx.doi.org/10.5468/ogs.20033

8	Clinicopathological characteristics of BRCA-associated breast cancer in Asian patients Eun-Kyu Kim, So Yeon Park, Sung-Won Kim J Pathol Transl Med.2020;54(4):265-275. Published online 2020 May 14 DOI: http://dx.doi.org/10.4132/jptm.2020.04.07

9	Germline PALB2, ATM variants in a patient with breast and ovarian cancer at risk for familial cancer syndrome: Is there a role for risk-reducing salpingo-oophorectomy? Semiramis L. Carbajal-Mamani, Merry J. Markham, Joaquín Santolaya-Forgas, Jacqueline C. Castagno, Joel Cardenas-Goicoechea Obstet Gynecol Sci.2020;63(2):205-208. Published online 2020 February 5 DOI: http://dx.doi.org/10.5468/ogs.2020.63.2.205

10	BRCA1/BRCA2 Pathogenic Variant Breast Cancer: Treatment and Prevention Strategies Anbok Lee, Byung-In Moon, Tae Hyun Kim Ann Lab Med.2020;40(2):114-121. Published online 2019 October 23 DOI: http://dx.doi.org/10.3343/alm.2020.40.2.114

11	Prevalence and oncologic outcomes of BRCA1/2 mutation and variant of unknown significance in epithelial ovarian carcinoma patients in Korea Jun Hyeong Seo, Soo Young Jeong, Myeong Seon Kim, Jun Hyeok Kang, E Sun Paik, Yoo-Young Lee, Tae-Joong Kim, Jeong-Won Lee, Byoung-Gie Kim, Duk-Soo Bae, Chel Hun Choi Obstet Gynecol Sci.2019;62(6):411-419. Published online 2019 October 11 DOI: http://dx.doi.org/10.5468/ogs.2019.62.6.411

12	Contralateral Breast Cancer and Ipsilateral Breast Tumor Recurrence in BRCA1/2 Carriers and Non-Carriers at High-Risk of Hereditary Breast Cancer Kyung-Hwak Yoon, Sumin Chae, Eunyoung Kang, Hee-Chul Shin, Jee Hyun Kim, In Ah Kim, So Yeon Park, Sung-Won Kim, Eun-Kyu Kim J Breast Cancer.2019;22(4):587-598. Published online 2019 September 30 DOI: http://dx.doi.org/10.4048/jbc.2019.22.e47

13	Trends in contralateral prophylactic mastectomy rate according to clinicopathologic and socioeconomic status Ho Jong Jeon, Hyung Seok Park, Ji Soo Park, Eun Ji Nam, Seung-Tae Lee, Jeongwoo Han Ann Surg Treat Res.2019;97(3):113-118. Published online 2019 August 29 DOI: http://dx.doi.org/10.4174/astr.2019.97.3.113

14	An optimized BRCA1/2 next-generation sequencing for different clinical sample types Yoonjung Kim, Chi-Heum Cho, Jung-Sook Ha, Do-Hoon Kim, Sun Young Kwon, Seoung Chul Oh, Kyung-A Lee J Gynecol Oncol.2020;31(1):e9. Published online 2019 August 6 DOI: http://dx.doi.org/10.3802/jgo.2020.31.e9

15	Maintenance of pegylated liposomal doxorubicin/carboplatin in patients with advanced ovarian cancer: randomized study of an Asian Gynecologic Oncology Group Chyong-Huey Lai, Elizabeth Vallikad, Hao Lin, Lan-Yan Yang, Shih-Ming Jung, Hsueh-Erh Liu, Yu-Che Ou, Hung-Hsueh Chou, Cheng-Tao Lin, Huei-Jean Huang, Kuan-Gen Huang, Jiantai Qiu, Yao-Ching Hung, Tzu-I Wu, Wei-Yang Chang, Kien-Thiam Tan, Chiao-Yun Lin, Angel Chao, Chee-Jen Chang J Gynecol Oncol.2020;31(1):e5. Published online 2019 July 26 DOI: http://dx.doi.org/10.3802/jgo.2020.31.e5

16	Novel Germline Mutations of BRCA1 and BRCA2 in Korean Familial Breast Cancer Patients Hee Nam Kim, Min-Ho Shin, Ran Lee, Min-Ho Park, Sun-Seog Kweon Chonnam Med J.2019;55(2):99-103. Published online 2019 May 23 DOI: http://dx.doi.org/10.4068/cmj.2019.55.2.99

17	Clinical and Genetic Characteristics of BRCA1/2 Mutation in Korean Ovarian Cancer Patients: A Multicenter Study and Literature Review Byung Su Kwon, Jung Mi Byun, Hyun Joo Lee, Dae Hoon Jeong, Tae Hwa Lee, Kyung-Hwa Shin, Dong Soo Suh, Ki Hyung Kim Cancer Res Treat.2019;51(3):941-950. Published online 2018 October 8 DOI: http://dx.doi.org/10.4143/crt.2018.312

18	Expression of DNA Damage Response Proteins and Associations with Clinicopathologic Characteristics in Chinese Familial Breast Cancer Patients with BRCA1/2 Mutations Xinyi Zhu, Tian Tian, Miao Ruan, Jia Rao, Wentao Yang, Xu Cai, Menghong Sun, Guangqi Qin, Zhonghua Zhao, Jiong Wu, Zhimin Shao, Ruohong Shui, Zhen Hu J Breast Cancer.2018;21(3):297-305. Published online 2018 September 12 DOI: http://dx.doi.org/10.4048/jbc.2018.21.e38

19	The Novel Pathogenic Mutation c.849dupT in BRCA2 Contributes to the Nonsense-Mediated mRNA Decay of BRCA2 in Familial Breast Cancer Sanrong Li, Jing Ma, Caiying Hu, Xing Zhang, Deyong Xiao, Lili Hao, Wenjun Xia, Jichun Yang, Ling Hu, Xiaowei Liu, Minghui Dong, Duan Ma, Rensheng Liu J Breast Cancer.2018;21(3):330-333. Published online 2018 August 28 DOI: http://dx.doi.org/10.4048/jbc.2018.21.e33

20	Status of BRCA1/2 Genetic Testing Practices in Korea (2014) Kyungju Lee, Ja-Hyun Jang, Seung-Tae Lee, Kyong-Ah Yoon, Eun Sook Lee, Jong-Won Kim, Sun-Young Kong Lab Med Online.2018;8(3):107-113. Published online 2018 July 19 DOI: http://dx.doi.org/10.3343/lmo.2018.8.3.107